Global Pancreatic Enzyme Replacement Therapy Market, By Type (Enteric Coated and Non-Enteric Coated), Treatment (Medication, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.
Pancreatic Enzyme Replacement Therapy Market Analysis and Size
The increased prevalence of rare diseases has significantly contributed to the use of enzyme replacement therapies, and medical research is projected to accelerate this progress further. As per the estimates from Genetic Alliance U.K., a single rare disease is projected to affect over 30,000 individuals in the U.K. It has been witnessed and observed that most chronic diseases are life-threatening, and timely medical treatment is essential to reduce mortality rates. Increasing use of several pancreatic enzymes such as lipase, amylase, and protease are used for the treatment of exocrine pancreatic insufficiency (EPI), which is seen commonly in cancer patients.
Data Bridge Market Research analyses a growth rate in the pancreatic enzyme replacement therapy market in the forecast period 2023-2030. The expected CAGR of the pancreatic enzyme replacement therapy market tends to be around 7.2% in the mentioned forecast period. The market was valued at USD 9.3 billion in 2022 and would grow to USD 16.22 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pancreatic Enzyme Replacement Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Enteric Coated and Non-Enteric Coated), Treatment (Medication, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Cigna (U.S.), Shire Pharmaceuticals Limited (U.S.), Sanofi (France)., BioMarin (U.S.)., Alexion Pharmaceuticals, Inc (U.S.)., AbbVie Inc. (U.S.), Horizon Therapeutics plc (U.S.), Janssen Global Services, LLC (U.S.), Recordati Rare Diseases (Italy), Protalix Biotherapeutics (Israel), Amicus Therapeutics, Inc (U.S.), Jasper Therapeutics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The pancreatic enzyme replacement therapy belongs to the type of medications that contain enzymes to replace when the pancreas can no longer release or produce enzymes naturally. These type of medications that contain proteases to digest protein, amylases to digest carbohydrates and lipases to digest fat. The food is not able to fully digest in the absence of pancreatic enzymes and all the nutrients and calories that are present in the food are not able to absorb properly and said as ‘malabsorption.’.
Global Pancreatic Enzyme Replacement Therapy Market Dynamics
Drivers
- Prevalence of Rare Diseases
According to Genetic Alliance UK records, a single rare disease is projected to affect over 30,000 individuals in the U.K. The most commonly occurring lysosomal storage diseases include Gaucher, Pompe, Fabry, and SCID diseases. Rare diseases such as these types occur in low frequencies. For instance, according to Orphanet, Gaucher’s disease is projected to be widespread in 1 individual in over 100,000 individuals. The low incidence of rare or orphan diseases is one of the major factors for its limited growth in the pharmaceutical industry.
- Increasing Cases of Chronic Diseases and Cancer
The growing prevalence of chronic diseases and cancer occurrence is estimated to boost the market's growth during the forecast period. For instance, according to the National Cancer Institute (NCI), in 2016, there were an estimated 15.5 million cancer cases that have been occurred in the U.S. Additionally, NCI records say that, in 2017, around 15,270 children and adolescents of the age group of 0 to 19 were diagnosed with cancer in the U.S. Furthermore, according to the International Diabetes Federation (IDF), in 2017, more than 425 million adults suffered from diabetes globally, and this is expected to reach 629 million by 2045. Thus, it boosts market growth.
Opportunities
- Increased Pancreatic Cancer And The Use of Enzymes
Increasing use of pancreatic enzymes such as amylase, lipase, and protease are used to treat exocrine pancreatic insufficiency (EPI), which is commonly seen in cancer patients. According to the records of American Cancer Society, over 55,440 individuals were expected to be diagnosed with pancreatic cancer in the year 2018. Increasing incidence of pancreatic cancer is thus anticipated to drive market growth during the forecast period.
Restraints/Challenges
- Risk of Complications
There is a severe high risk of complications associated with the use fo enzyme replacement therapies. Severe Complications such as skin reactions, increased risk of blood clots, sleep apnea, and many others are witnessed post the therapy. Thus, it hampers market growth.
- High Cost
The huge expenditure associated with gene therapies obstructs the market growth. Most pancreatic enzyme replacement therapy products are from the U.S. and are covered under reimbursement policies. Though, patients who do not have insurance find it difficult to afford such treatments.
This pancreatic enzyme replacement therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pancreatic enzyme replacement therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Pancreatic Enzyme Replacement Therapy Market Scope
The pancreatic enzyme replacement therapy market is segmented on the basis of type, treatment, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Enteric Coated
- Non-Enteric Coated
Treatment
- Medication
- Therapy
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Pancreatic Enzyme Replacement Therapy Market Regional Analysis/Insights
The pancreatic enzyme replacement therapy market is analyzed and market size insights and trends are provided by type, treatment, route of administration and end-user as referenced above.
The major countries covered in the pancreatic enzyme replacement therapy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for the pancreatic enzyme replacement therapy market throughout the forecast period due to the presence of key manufacturers of the product, high research and development and healthcare expenditure and skilled professionals.
Asia-Pacific dominates the market due to increased technological advancement and the increasing prevalence of chronic and metabolic diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Pancreatic Enzyme Replacement Therapy Market Share Analysis
The pancreatic enzyme replacement therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pancreatic enzyme replacement therapy market
Key players operating in the pancreatic enzyme replacement therapy market include:
- Cigna (U.S.)
- Shire Pharmaceuticals Limited (U.S.)
- Sanofi (France)
- BioMarin (U.S.)
- Alexion Pharmaceuticals, Inc (U.S.)
- AbbVie Inc. (U.S.)
- Horizon Therapeutics plc (U.S.)
- Janssen Global Services, LLC (U.S.)
- Recordati Rare Diseases (Italy)
- Protalix Biotherapeutics (Israel)
- Amicus Therapeutics, Inc (U.S.)
- Jasper Therapeutics, Inc. (U.S.)
SKU-